GO:0070442 integrin alphaIIb-beta3 complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0070442 (integrin alphaIIb-beta3 complex) is a platelet-specific heterodimeric integrin composed of one ITGA2B (alphaIIb) subunit and one ITGB3 (beta3) subunit.
• The complex is the major fibrinogen receptor on platelets and is essential for platelet aggregation and hemostasis.
• Loss or dysfunction of the complex causes Glanzmann thrombasthenia, a severe bleeding disorder.
• The alphaIIb and beta3 genes are not closely linked, yet their protein products must assemble into a functional heterodimer.
• Cytoplasmic and transmembrane interactions between alphaIIb and beta3 regulate integrin activation through a salt-bridge mechanism.
• CRISPR-based knockout, point-mutation, and knock-in models enable precise dissection of alphaIIb-beta3 structure, function, and disease variants.
Description
The integrin alphaIIb-beta3 complex (GO:0070442) is a heterodimeric cell-surface receptor that belongs to the integrin family of adhesion molecules. It is composed of one alphaIIb subunit (encoded by ITGA2B) and one beta3 subunit (encoded by ITGB3), and it is the most abundant integrin on the platelet surface. This complex functions as the primary receptor for fibrinogen and von Willebrand factor, making it indispensable for platelet aggregation and normal hemostasis. Because of its central role in thrombosis and bleeding, the alphaIIb-beta3 complex has been a major focus of platelet biology and antithrombotic drug development. At the molecular level, the alphaIIb-beta3 complex undergoes dynamic conformational changes that convert it from a low-affinity to a high-affinity ligand-binding state. This activation process is regulated by intracellular signals that impinge on the cytoplasmic tails of the two subunits, and it involves a conserved salt bridge between the alphaIIb and beta3 cytoplasmic domains. Structural and NMR studies have provided detailed insights into how the transmembrane and cytoplasmic regions of alphaIIb and beta3 interact to maintain the resting state and how these interactions are disrupted during activation. For researchers, GO:0070442 provides a precise ontological handle for annotating genes, proteins, and cellular components involved in platelet integrin biology. Understanding the composition, assembly, and regulation of this complex is critical for interpreting genetic variants associated with bleeding disorders and for designing targeted therapeutics. The complex also serves as a paradigm for studying integrin activation mechanisms more broadly.
integrin alphaIIb-beta3 complex At A Glance
| GO ID | GO:0070442 |
|---|---|
| GO term | integrin alphaIIb-beta3 complex |
| Ontology | cellular_component |
| Synonym | alphaIIb-beta3 integrin complex; ITGA2B-ITGB3 complex |
| Definition | An integrin complex that comprises one alphaIIb subunit and one beta3 subunit. |
| Major function | Fibrinogen receptor mediating platelet aggregation and hemostasis. |
| Subunit composition | One ITGA2B (alphaIIb) subunit and one ITGB3 (beta3) subunit. |
| Cellular location | Platelet plasma membrane, including focal adhesions and alpha-granule membranes. |
| Associated diseases | Glanzmann thrombasthenia; macrothrombocytopenia with enlarged alpha-granules. |
What Is GO:0070442?
The integrin alphaIIb-beta3 complex is a heterodimeric integrin complex that consists of exactly one alphaIIb subunit and one beta3 subunit. It is a cellular component located at the platelet plasma membrane and is also known as the alphaIIb-beta3 integrin complex or the ITGA2B-ITGB3 complex.
Why Is integrin alphaIIb-beta3 complex Important in Cell Biology?
The integrin alphaIIb-beta3 complex is the central receptor for platelet aggregation and thrombus formation, making it a key target for antiplatelet therapies and a critical determinant of bleeding risk. Genetic defects in ITGA2B or ITGB3 cause Glanzmann thrombasthenia, a severe inherited bleeding disorder characterized by absent platelet aggregation. Beyond disease, the complex is a model system for understanding integrin activation, inside-out signaling, and transmembrane allostery, with implications for cell adhesion, migration, and cancer biology.
• Mediates platelet aggregation by binding fibrinogen and von Willebrand factor.
• Essential for primary hemostasis and prevention of spontaneous bleeding.
• Loss-of-function mutations cause Glanzmann thrombasthenia.
• Specific intracytoplasmic salt-bridge mutations cause macrothrombocytopenia and enlarged alpha-granules.
• Serves as a therapeutic target for antiplatelet drugs such as abciximab, eptifibatide, and tirofiban.
• Provides a structural paradigm for integrin activation and inside-out signaling.
• Involved in outside-in signaling that regulates platelet spreading, clot retraction, and granule secretion.
• The ITGA2B and ITGB3 genes are not closely linked, yet their products must assemble into a functional complex.
• Cytoplasmic domain interactions regulate the resting and active states of the integrin.
• CRISPR models enable precise testing of patient-derived variants in the endogenous locus.
What Happens During integrin alphaIIb-beta3 complex?
Biosynthesis and Assembly of alphaIIb and beta3 Subunits
In simple terms: The two protein chains that make up the receptor are produced separately and then join together inside the cell.
The alphaIIb subunit is encoded by ITGA2B and the beta3 subunit by ITGB3. Although these genes are not closely linked in the genome, their protein products must assemble into a heterodimer in the endoplasmic reticulum. Proper assembly is required for transport of the complex to the platelet surface. Mutations that impair subunit synthesis or heterodimer formation lead to Glanzmann thrombasthenia.
Conformational Activation and Inside-Out Signaling
In simple terms: Signals from inside the platelet change the shape of the receptor so it can grab onto fibrinogen outside the cell.
In resting platelets, the alphaIIb-beta3 complex is in a bent, low-affinity conformation. Agonist-induced inside-out signaling through the cytoplasmic tails of alphaIIb and beta3 disrupts a conserved salt bridge, leading to extension and opening of the ligand-binding headpiece. This conformational change enables high-affinity binding to fibrinogen and von Willebrand factor, which is essential for platelet aggregation.
Ligand Binding and Platelet Aggregation
In simple terms: Once activated, the receptor binds fibrinogen, causing platelets to stick together and form a plug.
Activated alphaIIb-beta3 binds soluble fibrinogen and von Willebrand factor. Because fibrinogen is multivalent, it can bridge adjacent platelets, leading to aggregation and thrombus formation. This process is the final common pathway of platelet aggregation and is targeted by antiplatelet drugs such as abciximab, eptifibatide, and tirofiban.
Outside-In Signaling and Post-Aggregation Events
In simple terms: After binding its ligand, the receptor sends signals back into the platelet to stabilize the clot.
Ligand binding triggers outside-in signaling through the beta3 cytoplasmic tail, leading to cytoskeletal reorganization, platelet spreading, clot retraction, and granule secretion. These events reinforce platelet-platelet contacts and contribute to the stability of the hemostatic plug. The cytoplasmic binding partners of alphaIIb-beta3, including talin and kindlin, are critical for these signaling events.
Key Genes Involved in GO:0070442 integrin alphaIIb-beta3 complex
The following genes and proteins are directly involved in the structure, regulation, and function of the integrin alphaIIb-beta3 complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ITGA2B | Encodes the alphaIIb subunit of the complex | Mutations cause Glanzmann thrombasthenia; target for knockout and point-mutation studies |
| ITGB3 | Encodes the beta3 subunit of the complex | Mutations cause Glanzmann thrombasthenia; essential for heterodimer formation |
| FGA | Fibrinogen alpha chain; ligand for alphaIIb-beta3 | Mediates platelet aggregation; used in binding assays |
| FGB | Fibrinogen beta chain; ligand for alphaIIb-beta3 | Mediates platelet aggregation; used in binding assays |
| FGG | Fibrinogen gamma chain; ligand for alphaIIb-beta3 | Contains the RGD-like sequence recognized by the integrin |
| VWF | Von Willebrand factor; ligand for alphaIIb-beta3 | Supports platelet adhesion and aggregation under shear |
| TLN1 | Talin-1; binds beta3 cytoplasmic tail | Activates integrin by disrupting the salt bridge |
| FERMT3 | Kindlin-3; binds beta3 cytoplasmic tail | Required for integrin activation in platelets |
| GPVI | Collagen receptor that signals to activate alphaIIb-beta3 | Upstream activator of inside-out signaling |
| ITGB3 (isoform beta3) | Beta3 subunit also partners with alphaV | Distinct from alphaIIb-beta3 but shares the beta3 tail |
| SLC7A11 | Not directly related; placeholder for context | Not applicable to this complex; omitted from functional claims |
| RAP1B | Small GTPase involved in inside-out signaling | Regulates talin recruitment to beta3 |
| P2RY12 | ADP receptor that amplifies platelet activation | Indirectly promotes alphaIIb-beta3 activation |
| PTGS1 | Cyclooxygenase-1; produces thromboxane A2 | Amplifies platelet activation and integrin activation |
| ITGA2B (isoform) | AlphaIIb subunit variant | Splice variants may affect assembly |
| ITGB3 (isoform) | Beta3 subunit variant | Splice variants may affect assembly |
| CALR | Calreticulin; chaperone for integrin folding | Supports assembly of the heterodimer |
| CANX | Calnexin; chaperone for integrin folding | Supports assembly of the heterodimer |
How Is integrin alphaIIb-beta3 complex Regulated?
The activity of the integrin alphaIIb-beta3 complex is tightly regulated by inside-out signaling pathways. Agonist stimulation of platelet receptors such as GPVI and P2RY12 leads to activation of Rap1b and talin, which bind to the beta3 cytoplasmic tail and disrupt the alphaIIb-beta3 salt bridge, thereby switching the integrin to a high-affinity state. The intracytoplasmic salt bridge between alphaIIb and beta3 is a key structural element that maintains the resting state; mutations that disrupt this bridge cause constitutive activation and lead to macrothrombocytopenia with enlarged alpha-granules. NMR and crystal structures have revealed that the transmembrane and cytoplasmic domains of alphaIIb and beta3 form a heterocomplex that must be separated for activation. Additionally, the RGD sequence motif in ligands such as fibrinogen is recognized by the activated integrin, and modulation of this motif regulates disintegrin recognition.
integrin alphaIIb-beta3 complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ITGA2B | Glanzmann thrombasthenia; macrothrombocytopenia | Knockout or point-mutation knock-in in megakaryocytic cell lines |
| ITGB3 | Glanzmann thrombasthenia; macrothrombocytopenia | Knockout or point-mutation knock-in in megakaryocytic cell lines |
| ITGA2B/ITGB3 | Defective platelet aggregation | Patient-derived iPSC-derived megakaryocytes |
| ITGB3 | Altered alpha-granule morphology | Knock-in of salt-bridge mutations in mouse models |
| FGA/FGB/FGG | Dysfibrinogenemia affecting platelet aggregation | Overexpression of mutant fibrinogen in cell models |
Glanzmann Thrombasthenia
Glanzmann thrombasthenia is an autosomal recessive bleeding disorder caused by mutations in ITGA2B or ITGB3 that lead to absent or dysfunctional alphaIIb-beta3 complexes. Patients present with mucocutaneous bleeding, prolonged bleeding time, and absent platelet aggregation in response to physiological agonists. Management includes platelet transfusions, recombinant factor VIIa, and antifibrinolytics.
Macrothrombocytopenia with Enlarged alpha-Granules
Specific mutations in the intracytoplasmic salt bridge of alphaIIb-beta3 cause a distinct phenotype characterized by macrothrombocytopenia and enlarged platelet alpha-granules. This highlights the importance of the cytoplasmic domain interactions in regulating integrin function and platelet formation.
Thrombosis and Antiplatelet Therapy
The alphaIIb-beta3 complex is the target of antiplatelet drugs used in acute coronary syndromes and percutaneous coronary intervention. Excessive or inappropriate activation of the complex contributes to arterial thrombosis, making it a key therapeutic target.
From integrin alphaIIb-beta3 complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of ITGA2B abolish platelet aggregation? | ITGA2B knockout in megakaryocytic cell line (e.g., HEL, MEG-01) |
| Does a specific salt-bridge mutation cause constitutive activation? | Point-mutation knock-in of ITGA2B or ITGB3 in iPSC-derived megakaryocytes |
| Can a patient variant be corrected by gene editing? | Knock-in of wild-type ITGA2B or ITGB3 in patient iPSCs |
| Where is the complex localized during platelet spreading? | Tagged knock-in of ITGA2B with fluorescent protein |
| Does overexpression of beta3 increase fibrinogen binding? | Overexpression of ITGB3 in CHO or HEK293 cells |
| What is the role of the beta3 cytoplasmic tail in outside-in signaling? | Knockout of ITGB3 followed by rescue with tail mutants |
How to Study the integrin alphaIIb-beta3 complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Flow cytometry | Surface expression and activation state of alphaIIb-beta3 | Diagnosis of Glanzmann thrombasthenia; screening mutants |
| Light transmission aggregometry | Platelet aggregation in response to agonists | Functional assessment of integrin activity |
| NMR spectroscopy | Structure and dynamics of cytoplasmic heterocomplex | Mechanistic studies of integrin activation |
| X-ray crystallography | Atomic structure of transmembrane-cytoplasmic domains | Understanding salt-bridge regulation |
| CRISPR knockout | Loss-of-function phenotype | Identifying genes required for complex assembly |
| CRISPR knock-in | Effect of specific patient mutations | Modeling Glanzmann thrombasthenia variants |
| Proteomics | Interacting proteins and post-translational modifications | Identifying novel regulators of alphaIIb-beta3 |
| Bioinformatics | Variant pathogenicity prediction | Prioritizing mutations in ITGA2B and ITGB3 |
Flow Cytometry and Ligand-Binding Assays
Flow cytometry using fluorescently labeled fibrinogen or PAC-1 antibody can measure the activation state of alphaIIb-beta3 on the platelet surface. This method is widely used to diagnose Glanzmann thrombasthenia and to assess the effects of mutations.
Structural Biology (NMR and Crystallography)
NMR spectroscopy and X-ray crystallography have been used to determine the structure of the alphaIIb-beta3 transmembrane-cytoplasmic heterocomplex, revealing the salt bridge and its disruption during activation. These methods provide atomic-level insights into integrin regulation.
Platelet Aggregation and Functional Assays
Light transmission aggregometry measures platelet aggregation in response to agonists such as ADP, collagen, and thrombin. Absent aggregation is a hallmark of Glanzmann thrombasthenia. These assays are essential for functional validation of CRISPR-edited platelets or megakaryocytes.
CRISPR Screening and Bioinformatics
Genome-wide CRISPR knockout screens in megakaryocytic cell lines can identify genes required for alphaIIb-beta3 surface expression and function. Bioinformatics analysis of patient variants helps prioritize pathogenic mutations in ITGA2B and ITGB3.
How CRISPR Can Be Used to Study GO:0070442 integrin alphaIIb-beta3 complex
Knockout
CRISPR-Cas9 knockout of ITGA2B or ITGB3 in megakaryocytic cell lines or iPSCs abolishes surface expression of the alphaIIb-beta3 complex, mimicking Glanzmann thrombasthenia. These models are used to study the role of the complex in platelet aggregation and to test rescue strategies.
Point Mutation
Point mutations identified in patients with Glanzmann thrombasthenia or macrothrombocytopenia can be introduced into the endogenous ITGA2B or ITGB3 locus using CRISPR base editing or homology-directed repair. This allows precise testing of the functional consequences of specific amino acid changes, such as those disrupting the intracytoplasmic salt bridge.
Knock-in
Knock-in of a fluorescent tag (e.g., GFP) into ITGA2B or ITGB3 enables real-time imaging of the complex in live platelets or megakaryocytes. Knock-in of wild-type alleles can also correct disease-causing mutations in patient-derived iPSCs for disease modeling and drug screening.
Overexpression
Overexpression of ITGA2B and ITGB3 in heterologous cells such as CHO or HEK293 cells is used to study ligand binding, integrin activation, and the effects of mutations in a controlled background. This approach has been instrumental in defining the RGD recognition specificity of the complex.
How EDITGENE Supports integrin alphaIIb-beta3 complex Research
Researchers studying integrin alphaIIb-beta3 complex-related genes often need to determine whether a candidate gene is causally involved in platelet function, bleeding disorders, or thrombosis. EDITGENE provides a comprehensive suite of CRISPR-based services to accelerate this research, from knockout to precise point mutations and knock-in models.
Contact EDITGENE today to design your custom CRISPR model for integrin alphaIIb-beta3 complex research.
Frequently Asked Questions About integrin alphaIIb-beta3 complex
What is the integrin alphaIIb-beta3 complex?
The integrin alphaIIb-beta3 complex (GO:0070442) is a heterodimeric cell-surface receptor composed of one alphaIIb subunit and one beta3 subunit. It is the major fibrinogen receptor on platelets and is essential for platelet aggregation and hemostasis.
What genes are involved in the integrin alphaIIb-beta3 complex?
The complex is encoded by the ITGA2B gene (alphaIIb subunit) and the ITGB3 gene (beta3 subunit).
What is the function of the integrin alphaIIb-beta3 complex?
It mediates platelet aggregation by binding fibrinogen and von Willebrand factor, and it also transduces outside-in signals that stabilize platelet plugs.
What diseases are associated with the integrin alphaIIb-beta3 complex?
Mutations in ITGA2B or ITGB3 cause Glanzmann thrombasthenia, a severe bleeding disorder. Specific mutations in the cytoplasmic salt bridge cause macrothrombocytopenia with enlarged alpha-granules.
How is the integrin alphaIIb-beta3 complex activated?
Inside-out signaling through the cytoplasmic tails of alphaIIb and beta3 disrupts a conserved salt bridge, leading to conformational extension and high-affinity ligand binding.
What is the structure of the integrin alphaIIb-beta3 complex?
It is a heterodimer with one alphaIIb and one beta3 subunit. The transmembrane and cytoplasmic domains form a heterocomplex that is stabilized by a salt bridge in the resting state.
What is Glanzmann thrombasthenia?
Glanzmann thrombasthenia is an autosomal recessive bleeding disorder caused by absent or dysfunctional alphaIIb-beta3 complexes due to mutations in ITGA2B or ITGB3.
How can CRISPR be used to study the integrin alphaIIb-beta3 complex?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of the complex's assembly, activation, and role in disease.
What are the ligands of the integrin alphaIIb-beta3 complex?
The major ligands are fibrinogen and von Willebrand factor, which contain RGD-like sequences recognized by the activated integrin.
Where is the integrin alphaIIb-beta3 complex located?
It is located on the platelet plasma membrane, including focal adhesions and alpha-granule membranes.
Conclusion
The integrin alphaIIb-beta3 complex (GO:0070442) is a platelet-specific heterodimeric receptor that plays a central role in hemostasis and thrombosis. Its assembly, activation, and signaling are regulated by precise molecular interactions, including a conserved cytoplasmic salt bridge. Dysregulation of this complex causes severe bleeding disorders such as Glanzmann thrombasthenia and macrothrombocytopenia. CRISPR-based models are powerful tools for studying these mechanisms and for developing targeted therapies.
References
- 1. Watson SP et al.. 2005. GPVI and integrin alphaIIb beta3 signaling in platelets.. J Thromb Haemost 3(8):1752-62 PMID: 16102042
- 2. Bonner MA et al.. 2007. Cytoplasmic binding partners of the platelet integrin alphaIIb beta3.. Front Biosci 12:2038-49 PMID: 17127442
- 3. Favier M et al.. 2018. Mutations of the integrin αIIb/β3 intracytoplasmic salt bridge cause macrothrombocytopenia and enlarged platelet α-granules.. Am J Hematol 93(2):195-204 PMID: 29090484
- 4. Thornton MA et al.. 1999. The human platelet alphaIIb gene is not closely linked to its integrin partner beta3.. Blood 94(6):2039-47 PMID: 10477733
- 5. Di Minno G et al.. 2009. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues.. Thromb Haemost 102(6):1157-64 PMID: 19967146
- 6. Metcalf DG et al.. 2010. NMR analysis of the alphaIIb beta3 cytoplasmic interaction suggests a mechanism for integrin regulation.. Proc Natl Acad Sci U S A 107(52):22481-6 PMID: 21156831
- 7. Yang J et al.. 2009. Structure of an integrin alphaIIb beta3 transmembrane-cytoplasmic heterocomplex provides insight into integrin activation.. Proc Natl Acad Sci U S A 106(42):17729-34 PMID: 19805198
- 8. Rahman S et al.. 1998. Modulation of RGD sequence motifs regulates disintegrin recognition of alphaIIb beta3 and alpha5 beta1 integrin complexes. Replacement of elegantin alanine-50 with proline, N-terminal to the RGD sequence, diminishes recognition of the alpha5 beta1 complex with restoration induced by Mn2+ cation.. Biochem J 335 ( Pt 2)(Pt 2):247-57 PMID: 9761721
